Compare National Beverage Corp. (FIZZ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Novo Nordisk A/S — how do they compare? National Beverage Corp. trades at $30.9 (market cap $2.91B), while Novo Nordisk A/S trades at $47.06 (market cap $207.31B). The key difference: Novo Nordisk A/S is far larger — about 71.2× National Beverage Corp.'s market cap, and Novo Nordisk A/S pays a 3.76% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| FIZZ | NVO | |
|---|---|---|
Market Cap | $2.91B | $207.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $46.75 | $63.98 |
52-Week Low | $30.53 | $35.29 |
Enterprise Value | $2.62B | $222.02B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $32.13, up 0.53% today, with neutral technical signals and mixed earnings performance. The company reported $1.20B revenue and $186.82M net income for 2025, maintaining strong profitability margins. Recent news highlights a special $3.25 dividend announcement amid concerns about LaCroix brand stagnation and competitive pressures.
The stock faces headwinds from declining volumes and muted growth prospects, offset by shareholder returns via dividends. Analyst sentiment is cautious with 50% sell ratings. Key risks include consumer weakness and tariff impacts, while valuation at 15.84x P/E appears reasonable given current fundamentals.
Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.
Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
